(HealthDay News) — For patients with long QT syndrome (LQTS), different β-blockers are effective for reducing the risk for first cardiac event in LQT1, but only nadolol is effective in LQT2, according to a study published in the September 30 issue of the Journal of the American College of Cardiology.

Abeer Abu-Zeitone, PhD, from the University of Rochester Medical Center in New York, and colleagues compared the efficacy of different β-blockers in LQTS and in genotype-positive patients with LQT1 and LQT2. Participants included 1,530 patients from a LQTS Registry.

The researchers found that, compared with being off β-blockers, the hazard ratios for first cardiac events were 0.71 (95% confidence interval [CI], 0.50–1.01) for atenolol; 0.70 (95% CI, 0.43–1.15) for metoprolol; 0.65 (95% CI, 0.46–0.90) for propranolol; and 0.51 (95% CI, 0.35–0.74) for nadolol. A similar risk reduction for first cardiac events was seen among the four β-blockers in LQT1, while in LQT2, the only significant risk reduction was seen for nadolol (hazard ratio, 0.40; 95% CI, 0.16–0.98). The efficacy for recurrent events differed by drug among patients who had a prior cardiac event while taking β-blockers (P=0.004), with propranolol the least effective.

“Although the four β-blockers are equally effective in reducing the risk of a first cardiac event in LQTS, their efficacy differed by genotype,” the authors write.

The study was partially funded by GeneDx.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)